Atea Pharmaceuticals Inc. (NASDAQ:AVIR)’s traded shares stood at 2.45 million during the last session. At the close of trading, the stock’s price was $41.03, to imply an increase of 2.91% or $1.16 in intraday trading. The AVIR share’s 52-week high remains $94.17, putting it -129.51% down since that peak but still an impressive 54.37% since price per share fell to its 52-week low of $18.72. The company has a valuation of $2.83B, with an average of 4.88 million shares in intraday trading volume over the past 10 days and average of 1.66 million shares over the past 3 months.
Analysts have given a consensus recommendation of an Overweight for Atea Pharmaceuticals Inc. (AVIR), translating to a mean rating of 1.60. Of 4 analyst(s) looking at the stock, 0 analyst(s) give AVIR a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.17.
Atea Pharmaceuticals Inc. (NASDAQ:AVIR) trade information
After registering a 2.91% upside in the last session, Atea Pharmaceuticals Inc. (AVIR) has traded red over the past five days. The stock hit a weekly high of 46.91 this Thursday, 10/07/21, jumping 2.91% in its intraday price action. The 5-day price performance for the stock is 17.03%, and 48.12% over 30 days. With these gigs, the year-to-date price performance is -1.80%. Short interest in Atea Pharmaceuticals Inc. (NASDAQ:AVIR) saw shorts transact 4.25 million shares and set a 11.26 days time to cover.
Analysts on Wall Street suggest a consensus price target of $57.00, implying an increase of 28.02% to the stock’s current value. The extremes give us $55.00 and $60.00 for target low and target high price respectively. As such, AVIR has been trading -46.23% off suggested target high and -34.05% from its likely low.
Atea Pharmaceuticals Inc. (AVIR) estimates and forecasts
Looking at statistics comparing Atea Pharmaceuticals Inc. share performance against respective industry, we note that the company has outperformed competitors. Atea Pharmaceuticals Inc. (AVIR) shares are -27.39% down over the last 6 months, with its year-to-date growth rate higher than industry average at 247.06% against 7.00%. The rating firms project that company’s revenue will grow 491.60% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is $53.46 million. Meanwhile, for the quarter ending Dec 2021, a total of 3 analyst(s) estimate revenue growth to $103.46 million.
Atea Pharmaceuticals Inc. has its next earnings report out on March 30. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Atea Pharmaceuticals Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Atea Pharmaceuticals Inc. (NASDAQ:AVIR)’s Major holders
Atea Pharmaceuticals Inc. insiders hold 18.48% of total outstanding shares, with institutional holders owning 58.09% of the shares at 71.26% float percentage. In total, 58.09% institutions holds shares in the company, led by FMR, LLC. As of Dec 30, 2020, the company held over 6.45 million shares (or 7.79% of shares), all amounting to roughly $269.38 million.
The next major institution holding the largest number of shares is Cormorant Asset Management, LP with 6.41 million shares, or about 7.75% of shares outstanding. As of the market price on Dec 30, 2020, these shares were worth $267.87 million.
We also have Fidelity Growth Company Fund and Fidelity Series Growth Company Fund as the top two Mutual Funds with the largest holdings of the Atea Pharmaceuticals Inc. (AVIR) shares. Going by data provided on Feb 27, 2021, Fidelity Growth Company Fund holds roughly 3.01 million shares. This is just over 3.64% of the total shares, with a market valuation of $226.82 million. Data from the same date shows that the other fund manager holds a little less at 0.66 million, or 0.80% of the shares, all valued at about 49.75 million.